Search results for "From I.M. Matters"


 
Results 1 - 10 of about 11 for "From I.M. Matters".
Sort by: Relevance | Newest | Oldest

Risk for CVD events elevated years before type 2 diabetes diagnosis

A Danish study found that patients with type 2 diabetes had a twofold higher prevalence of cardiovascular disease (CVD) events as long as three decades before their diagnosis versus matched comparators.
https://diabetes.acponline.org/archives/2024/12/13/7.htm
13 Dec 2024

Intensive BP control improved outcomes in patients with type 2 diabetes, trial finds

A composite of nonfatal stroke, nonfatal myocardial infarction, treatment or hospitalization for heart failure, or death from cardiovascular causes was significantly lower among patients treated to a blood pressure (BP) target of less than 120 mm Hg versus one below 140 mm Hg.
https://diabetes.acponline.org/archives/2024/12/13/6.htm
13 Dec 2024

Semaglutide shows promise for smoking cessation

Patients taking semaglutide were less likely to have a medical encounter that included a diagnosis of tobacco use disorder than patients taking any of seven other diabetes medications, a retrospective study found.
https://diabetes.acponline.org/archives/2024/08/09/8.htm
9 Aug 2024

Statin therapy alone does not appear to increase diabetes risk in patients with HIV and no other diabetes risk factors

An analysis of data from a randomized trial found that statin treatment affected risk for new-onset diabetes primarily among patients with HIV who had multiple metabolic risk factors.
https://diabetes.acponline.org/archives/2024/10/11/7.htm
11 Oct 2024

Differentiating type 1 from type 2 diabetes in adults

Type 1 diabetes appears in adulthood more often than previously thought and its overt symptoms tend to be milder than those in children, making diagnosis tricky.
https://diabetes.acponline.org/archives/2024/05/10/9.htm
10 May 2024

Studies look at weight loss, suicide risks for GLP-1s

A cohort study found significantly more weight loss in patients taking tirzepatide than semaglutide, while another analysis found no increased risk of suicide with glucagon-like peptide-1 (GLP-1) receptor agonists.
https://diabetes.acponline.org/archives/2024/08/09/7.htm
9 Aug 2024

Metformin safe for use while trying to conceive, studies find

Use of metformin by fathers was not associated with risk of major congenital malformation, and mothers who continued metformin and added insulin had lower risk of losing a baby than those who switched to insulin, according to two recent studies.
https://diabetes.acponline.org/archives/2024/07/12/7.htm
12 Jul 2024

SGLT-2 inhibitors more effective than sulfonylureas, DPP-4 inhibitors as second-line therapy

Patients with type 2 diabetes who added a sodium-glucose cotransporter-2 (SGLT-2) inhibitor to metformin had greater reductions in HbA1c level and body mass at one year than those who added a sulfonylurea or dipeptidyl peptidase-4 (DPP-4) inhibitor, a U.K. study found.
https://diabetes.acponline.org/archives/2024/06/14/7.htm
14 Jun 2024

Shifts in insulin use

Changes in technology and drug prices have affected how physicians manage patients with insulin-treated diabetes.
https://diabetes.acponline.org/archives/2024/02/09/7.htm
9 Feb 2024

Bariatric surgery improves long-term diabetes outcomes more than medication, lifestyle interventions

Patients who underwent bariatric surgery for type 2 diabetes had remission rates of 18.2% at seven years and 12.7% at 12 years, compared to 6.2% and 0%, respectively, in patients treated with medical and lifestyle interventions, a new review found.
https://diabetes.acponline.org/archives/2024/03/08/6.htm
8 Mar 2024

Result Page: Prev   1   Next